Anyone that doesn't believe there will be a reduction in Q4 of 2024 is kidding themselves. Xiidra is never going to grow. They paid a ton fo money for a product that they beleived would grow but never will due to increased generic pressure and more branded competition. Not to mention, the data for Xiidra simply isn't that impressive to begin with.
The axe is going to fall on a lot of legacy Novartis reps because their 12 month extended severence protection ends in October. The virtual sales team is a joke and a complete waste of money. They'll be gone. The green team or whichever team it is that's wasting time calling on Walmart optical, etc., will be gone too.
The sales force will consist of either 1 rep carrying the entire B&L portfolio plus a DES, or the DES team will be wiped out and they will continue with the two rep formula with 1 glaucoma rep and 1 dry eye rep. Get your resume ready (if it isn't already) and go look for a higher paying job with a better company now. Nearly every other company out there is paying more than B&L, so don't settle for being underpaid!